Cargando…
Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder primarily affecting dopaminergic neuronal systems, with impaired motor function as a consequence. The most effective treatment for PD remains the administration of oral levodopa (LD). Long-term LD treatment is frequently associate...
Autores principales: | Adamiak-Giera, Urszula, Jawień, Wojciech, Pierzchlińska, Anna, Białecka, Monika, Kobierski, Jan Dariusz, Janus, Tomasz, Gawrońska-Szklarz, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472364/ https://www.ncbi.nlm.nih.gov/pubmed/34575471 http://dx.doi.org/10.3390/pharmaceutics13091395 |
Ejemplares similares
-
Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
por: Kang, Suk Yun, et al.
Publicado: (2017) -
Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020) -
Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022) -
Elevated Homocysteine by Levodopa Is Detrimental to Neurogenesis in Parkinsonian Model
por: Shin, Jin Young, et al.
Publicado: (2012) -
Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson’s disease
por: Pierzchlińska, Anna, et al.
Publicado: (2021)